摘要
目的 :评估异基因外周血干细胞移植治疗急性白血病的疗效与卫生经济效率。 方法 :回顾性分析 2 0例缓解期急性白血病患者行人类白细胞抗原 (HL A )相合外周血干细胞移植 (移植组 )病例资料 ,另对应每例患者各选取 2例常规化疗病例(化疗组 )作对照 ,比较两组病例的预后及经济费用。 结果 :移植组 3年生存率、复发率分别为 (6 5 .3± 12 .4) %和(15 .6± 7.1) %,化疗组分别为 (2 9.5± 8.2 ) %和 (6 7.2± 5 .8) %,统计学分析有显著性差异 (P<0 .0 1) ,而比较两组病例的 3年治疗费用无明显差异 (P>0 .0 5 ) ;计算成本效果比 ,异基因外周血干细胞移植挽回 1例死亡所耗费成本为 48.7万元 ,明显低于常规化疗的 6 7.4万元。 结论 :异基因外周血干细胞移植疗效好 ,经济效率高。
Objective: To evaluate the therapeutic efficacy and cost-effectiveness of treating the acute leukemia with allogeneic peripheral blood stem cell transplantation (Allo-PBSCT). Methods:Twenty acute leukemia patients received Allo-PBSCT (transplantation group) and 40 patients received conventional chemotherapy (chemotherapy group) were analyzed retrospectively, and their therapeutic efficacy and medical cost were compared. Results:The 3 years survival rate and relapse rate of the transplant group were (65.3±12.4)% and (15.6±7.1)%, respectively, and those of the chemotherapy group were (29.5±8.2)% and (67.2±5.8)%, respectively, there was significant difference (P<0.01), but there was no significant difference in cost in 3 years(P>0.05); the cost/effectiveness of Allo-PBSCT per patient was 487 000 RMB, and that of chemotherapy was 674 000 RMB. Conclusion:Allo-PBSCT has good therapeutic efficacy, and its cost-effectiveness is also good.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2002年第9期946-948,共3页
Academic Journal of Second Military Medical University
基金
上海市卫生系统百名跨世纪优秀学科带头人培养计划资助项目 (98BR0 2 9)
关键词
造血干细胞
细胞移植
外周血
异基因
急性白血病
卫生经济学
治疗
hematopoietic stem cells
cell transplantation
peripheral blood
allogeneic
leukemia
health economics
treatment effectiveness
